PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer …